SBIR-STTR Award

Development of a new disabling device for use in human intradermal immunization programs
Award last edited on: 6/24/2020

Sponsored Program
SBIR
Awarding Agency
NIH
Total Award Amount
$701,800
Award Phase
2
Solicitation Topic Code
2011N13581
Principal Investigator
Fred Snyder

Company Information

SID Technologies LLC

2033 Trowbridge Drive
Newtown, PA 18940
   (267) 566-3546
   N/A
   N/A
Location: Single
Congr. District: 01
County: Bucks

Phase I

Contract Number: N/A
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2010
Phase I Amount
$100,000
No abstract available.

Phase II

Contract Number: 200-2011-41645
Start Date: 9/30/2011    Completed: 8/31/2013
Phase II year
2011
Phase II Amount
$601,800
SID Technologies is developing intradermal devices aiding healthcare workers in performing intradermal injections. The goal is to provide an alternative, easier to learn method of intradermal drug delivery to the Mantoux technique, in order to expand the population of healthcare workers who may deliver drugs intradermally. This, in tum, is expected to spare valuable doses of expensive, short-supply vaccines such as rabies, thereby stretching supplies and reaching more patients. A successful 10 delivery technology could also catalyze novel approaches for existing vaccines that could be used more widely, less expensively, and potentially more effectively through the 10 route. Auto Disable Intradermal adapter (AD 10 adapter) is intended for safe intradermal injection in conjunction with AD syringes. When used with AD syringes the AD ID adapter will prevent the potential reuse of the 10 device with a new syringe minimizing the occupational acquisition of patient infections as well as a potential for cross contamination of patients. The AD 10 adapter is envisioned as a single molded plastic part. The manufacture of the AD 10 adapter does not require any specialized technologies. The adapter could be introduced into developing world practice in a few years Immediately reducing the vaccination costs.